Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 7,529 | 51% |
| 2020 | 28 | 4,396 | 53% |
| 2021 | 30 | 5,450 | 57% |
| 2022 | 30 | 6,670 | 60% |
| 2023 | 28 | 6,077 | 64% |
| 2024 | 27 | 7,528 | 66% |
| 2025 from claims | – | 8,637 7,926–9,138 | 67% |
| 2026 forecast | – | 9,414 8,283–10,863 | 66% |
| 2027 forecast | – | 9,981 8,532–11,894 | 66% |
| 2028 forecast | – | 10,580 8,828–12,955 | 67% |
| 2029 forecast | – | 11,214 9,160–14,064 | 67% |
| 2030 forecast | – | 11,886 9,522–15,231 | 67% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 73% of the cases CMS names in Rhode Island; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 11% hospital outpatient, 48% surgery center, 41% office. The share outside the hospital has moved +6 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 588 | 82,565−2.7%/yr | −2.7%/yr | 44.5 | 75% | 85,900 in 2030+0.7%/yr |
| Pennsylvania | 390 | 72,726−1.7%/yr | −1.7%/yr | 52.4 | 80% | 74,300 in 2030+0.4%/yr |
| Massachusetts | 256 | 48,337+1.2%/yr | +1.2%/yr | 50.4 | 83% | 55,500 in 2030+2.3%/yr |
| New Jersey | 259 | 44,451−1.6%/yr | −1.6%/yr | 41.8 | 95% | 46,300 in 2030+0.7%/yr |
| Connecticut | 117 | 25,053−0.3%/yr | −0.3%/yr | 74.2 | 80% | 30,200 in 2030+3.2%/yr |
| New Hampshire | 45 | 10,8700%/yr | 0%/yr | 47.3 | 79% | 12,900 in 2030+2.8%/yr |
| Maine | 24 | 5,023−10%/yr | −10%/yr | 31.2 | 86% | 4,850 in 2030−0.6%/yr |
| Vermont | 17 | 4,085−6.1%/yr | −6.1%/yr | 35.4 | 63% | 6,680 in 2030+8.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 0 | 115−2.6%/yr | −2.6%/yr | 1.30.7× | 100% | 70 in 2030−8%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with New York
Alcon leads with 29% of company spending on these surgeons in 2025, −6 pts on 2024.
In 2025, 13 companies reported engagement with Rhode Island’s surgeons worth $47K in consulting, speaking, meals and travel tied to these products, about $1,758 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.